ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pelacarsen

Also written as “Pelacarsen”, “ISIS 681257” and “Pelacarsen (TQJ230)”.

Its studies are mostly in Cardiovascular Diseases · Atherosclerosis · Hyperlipoproteinemias · Acute Coronary Syndrome · Aortic Valve Stenosis, led by 2 companies.

Drug pagePelacarsen: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 16, 201916 company-led studies, 4 open or runningNext primary completion: Feb 3, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis104 open or runningphase 3since Jul 16, 2019Jul 16, 2019Feb 3, 2028phase 3 · NCT06813911
Ionis Pharmaceuticalsits history only60 open or runningphase 2since Jan 31, 2017Apr 1, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 16, 2019First study: phase 3 study in Cardiovascular DiseasesFirst studyNCT04023552 · 8,323 enrolled · United States, Argentina, Australia and more
  2. Dec 9, 2019Named pelacarsenINNProposed as its International Nonproprietary Name in WHO's List 122 · before, ISIS 681257, TQJ230
  3. Aug 4, 2021Phase 1 study in Hepatic ImpairmentNCT05026996 · 17 enrolled · United States
  4. Mar 14, 2022Phase 3 study in Cardiovascular DiseasesNCT05305664 · 51 enrolled · Germany
  5. Dec 2, 2022Phase 2 study in Aortic Valve StenosisNCT05646381 · 502 planned · United States, Austria, Belgium and more
  6. Jun 2, 2023Phase 3 study in HyperlipoproteinemiasNCT05900141 · 41 enrolled · Germany
  7. Feb 12, 2024Phase 3 study in Cardiovascular DiseasesNCT06267560 · 422 enrolled · United States, Puerto Rico
  8. Feb 3, 2025Phase 3 study in AtherosclerosisNCT06813911 · 246 enrolled · United States, China, France and more
  9. Mar 12, 2025Phase 3 study in AtherosclerosisNCT06875973 · 599 enrolled · United States, Puerto Rico
  10. Apr 1, 2026Phase 3 study in Cardiovascular DiseasesNCT07517263 · 5,700 enrolled · United States, Argentina, Australia and more
  11. May 27, 2026Phase 3 study in Acute Coronary SyndromeNCT07625306
  12. Oct 14, 2026Phase 3 study withdrawnStudy stoppedNCT07625306 · “Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint”
  13. Oct 14, 2026Primary completion moved from 2028-12-07 to 2029-01-22Date moved laterphase 3 · +2 months · NCT07625306
  14. Nov 10, 2026Phase 3 study terminatedStudy stoppedNCT05900141 · “Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint”

Ahead

  1. Feb 3, 2028Primary completion: phase 3 study in AtherosclerosisNCT06813911
  2. Jan 9, 2030Primary completion: phase 3 study in Cardiovascular DiseasesNCT07517263
  3. Mar 12, 2030Primary completion: phase 2 study in Aortic Valve StenosisNCT05646381
  4. Dec 8, 2030Primary completion: phase 3 study in AtherosclerosisNCT06875973

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07625306Acute Coronary Syndrome3WithdrawnJan 22, 20290
NCT07517263Cardiovascular Diseases · United States, Argentina, Australia and more3Active, not recruitingJan 9, 20305,700
NCT06875973Atherosclerosis · United States, Puerto Rico3Active, not recruitingDec 8, 2030599
NCT06813911Atherosclerosis · United States, China, France and more3Active, not recruitingFeb 3, 2028246
NCT06267560Cardiovascular Diseases · United States, Puerto Rico3CompletedMar 25, 2026422
NCT05900141Hyperlipoproteinemias · Germany3TerminatedOct 15, 202641
NCT05646381Aortic Valve Stenosis · United States, Austria, Belgium and more2RecruitingMar 12, 2030502
NCT05305664Cardiovascular Diseases · Germany3CompletedJan 28, 202551
NCT05026996Hepatic Impairment · United States1CompletedOct 19, 202217
NCT04023552Cardiovascular Diseases · United States, Argentina, Australia and more3CompletedJul 16, 20268,323

How it is read

Names in the registry

  • “Pelacarsen”, 5 entries
  • “ISIS 681257”, 4 entries
  • “Pelacarsen (TQJ230)”, 2 entries
  • “TQJ230”, 2 entries
  • “Pelacarsen (TQJ230) 80 mg s.c.”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.